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INTRODUCTION
It is now well established that infusion of donor lym-
phocytes provides an effective therapeutic approach in
patients with relapsed hematologic malignancies after allo-
geneic stem cell transplantation [1-3]. Responses are noted
most frequently in patients with chronic myelocytic
leukemia (CML); 60% to 80% of CML patients can achieve
Conversion to Full Donor Chimerism Following Donor
Lymphocyte Infusion Is Associated With Disease
Response in Patients With Multiple Myeloma
Enrica Orsini, Edwin P. Alyea, Antoinette Chillemi, Robert Schlossman, Stephen McLaughlin, 
Christine Canning, Robert J. Soiffer, Kenneth C. Anderson, Jerome Ritz
Center for Hematologic Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Correspondence and reprint requests: Jerome Ritz, MD, Dana-Farber Cancer Institute, 44 Binney St., 
Boston, MA 02115 (e-mail: jerome_ritz@dfci.harvard.edu).
(Received December 17, 1999; accepted March 14, 2000)
ABSTRACT
Donor lymphocyte infusions (DLIs) have been demonstrated to induce clinical responses in patients with relapsed
multiple myeloma after allogeneic bone marrow transplantation, but the immunologic mechanisms involved have
not been well characterized. In patients with chronic myelocytic leukemia (CML), remissions following DLI are
invariably associated with conversion to complete donor hematopoiesis, suggesting that the target antigens of this
response are expressed on both normal and CML-derived hematopoietic stem cells. In the present study, we exam-
ined hematopoietic chimerism and the complexity of the T-cell receptor (TCR) repertoire in 4 patients with
relapsed multiple myeloma who received infusions of donor CD4+ lymphocytes. Three of 4 patients had a clinical
response that began 1 to 2 months after DLI. All 3 responding patients developed lymphocytosis at the initiation of
response that was due to a 2- to 4.5-fold increase in the number of CD3+ T cells. In 1 patient, this was due primarily
to increases in CD3+ and CD8+ cells; in 2 patients, to increased numbers of CD3+ and CD8+ and CD3+ and CD4+
T cells. In all responding patients, conversion to complete donor hematopoiesis occurred in the first 2 months after
DLI. The single nonresponding patient remained at 100% recipient hematopoiesis. The TCR repertoire complexity
was examined by polymerase chain reaction amplification of complementary-determining region 3 (CDR3) derived
from 24 Vβ gene subfamilies. In 2 patients, the initiation of myeloma response and conversion to complete donor
hematopoiesis was associated with normalization of TCR complexity. Complete donor chimerism and normal TCR
complexity remained stable in all patients and did not change with subsequent relapse or development of graft-ver-
sus-host disease (GVHD). Thus, conversion to full donor chimerism was temporally associated with the anti-
myeloma effect of DLI but not with the development of GVHD. Nevertheless, the maintenance of stable donor
hematopoiesis did not prevent disease relapse and was not associated with prolonged remission. The selective
relapse of myeloma cells without concomitant return of mixed hematopoietic chimerism suggests that myeloma
tumor cells in some patients develop resistance to immune destruction.
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complete cytogenetic and molecular remission following
donor lymphocyte infusion (DLI) without other treatment
[2-4]. Clinical responses are less frequent in patients with
relapsed acute leukemia, but several reports have docu-
mented a relatively high rate of response in patients with
multiple myeloma [5-8]. In contrast to CML, however,
responses in multiple myeloma do not often result in com-
plete remission, and myeloma relapse is frequently noted
after an initial period of tumor response [9]. The different
responses of various hematologic malignancies may reﬂect
inherent differences in susceptibility to immune-mediated
destruction. Alternatively, these differences may reflect
the ability of malignant cells to develop resistance that
circumvents an initially effective immune response. Fur-
ther characterization of the target specificity of the graft-
versus-leukemia (GVL) and graft-versus-myeloma (GVM)
responses after DLI would help distinguish between these
alternative hypotheses.
To characterize the target speciﬁcity of GVL, previous
studies have examined patient-donor chimerism following
DLI [10-12]. In patients with CML, clinical response and
disappearance of leukemic cells has been closely associated
with elimination of mixed hematopoietic chimerism and con-
version to complete donor hematopoiesis [10,13,14]. This
observation suggests that an immune response, directed pri-
marily against allogeneic target antigens, possibly minor his-
tocompatibility antigens rather than tumor-speciﬁc antigens
is responsible for disease eradication after DLI [15-17]. In
CML, both malignant and normal hematopoietic pro-
genitor cells are presumed to have a similar antigenic pheno-
type, and this may explain the high degree of responsiveness
to DLI. However, multiple myeloma tumor cells represent a
lineage-restricted target and are less likely to be antigenically
similar to normal hematopoietic stem cells. We therefore
hypothesized that a detailed examination of hematopoietic
chimerism in patients with multiple myeloma would provide
additional insight into the target specificity of the GVM
immune response [18].
In the present study, we examined 4 patients with
relapsed multiple myeloma after allogeneic bone marrow
transplantation (BMT) who received infusions of CD4+
donor lymphocytes. Serial analysis of hematopoietic
chimerism, phenotype of peripheral blood lymphocytes, and
T-cell receptor (TCR) Vβ repertoire was undertaken in
these patients. Results obtained over a 2- to 3-year period
were correlated with the onset of myeloma response, graft-
versus-host disease (GVHD), and relapse after DLI. These
results suggest that the initial response to DLI in patients
with myeloma is directed at antigens expressed by both nor-
mal hematopoietic and tumor-derived recipient cells. The
frequent occurrence of relapse following DLI in multiple
myeloma may be due to the development of resistance to
immune-mediated destruction.
MATERIALS AND METHODS
CD4+ Donor Lymphocyte Infusions
The present studies were performed in 4 patients with
relapsed multiple myeloma who had undergone allogeneic
BMT from an HLA-identical sibling donor. Donor marrow
was depleted of CD6+ T cells in vitro, and patients received
no other prophylactic immunosuppressive therapy after BMT
[19,20]. After relapse, each patient was enrolled in a clinical
trial to evaluate the toxicity and immunologic effects of esca-
lating doses of allogeneic CD4+ lymphocytes [9]. Donor
T cells were obtained by leukapheresis from the same HLA-
identical sibling that had donated marrow for allogeneic
BMT. The method for depletion of CD8+ cells has been
described [9]. Patients described in this report received either
1 × 108 or 1.5 × 108 CD4+ cells/kg. DLIs contained <1%
CD8+ cells. DLIs were repeated at weekly intervals until the
targeted number of CD4+ T cells was administered. All other
therapy was discontinued before DLI, and patients received
no other immune-modulating therapy after DLI. The clinical
research protocol for this treatment was approved by the
Human Subjects Protection Committee of the Dana-Farber
Cancer Institute, and informed consent was obtained from
each patient and donor. Blood samples for in vitro experi-
ments were obtained from the donors and from the patients
before DLI and at different time points after DLI.
Phenotypic Analysis of Peripheral Blood Lymphocytes
Heparinized blood samples from patients were obtained
before and at various times after DLI. Peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque
density gradient centrifugation, cryopreserved with 10%
dimethyl sulfoxide (DMSO), and stored in vapor-phase liquid
nitrogen until the phenotypic and molecular analysis. For ﬂow
cytometric analysis, 0.5 to 1 × 106 PBMCs were incubated at
4°C for 30 minutes with murine monoclonal antibodies spe-
ciﬁc for CD3, CD4, and CD8 antigens conjugated to ﬂuores-
cein isothiocyanate or phycoerythrin (Coulter Immunology,
Hialeah, FL). Antibodies were used at 1:100 dilution, and cells
were washed with phosphate-buffered saline, followed by ﬁxa-
tion with 2% paraformaldehyde. Immunophenotypic analysis
of the stained and fixed cells was performed on a Coulter
EPICS XL Flow Cytometer (Beckman Coulter, Hialeah, FL).
Absolute numbers of T-cell subsets in peripheral blood sam-
ples were calculated after determining the percent positive
cells by ﬂow cytometry and the absolute number of mononu-
clear cells from an automated complete blood cell count dif-
ferential obtained on the same day.
Hematopoietic Chimerism Assay
Genomic DNA was extracted from 3 to 10 × 106 PBMCs
according to the manufacturer’s recommendations (Wizard
Genomic DNA Purification Kit; Promega, Madison, WI).
Before ampliﬁcation, DNA in each sample was quantitated
by ultraviolet spectrophotometry and diluted to working
concentrations. DNA from each donor-recipient pair was
ampliﬁed by polymerase chain reaction (PCR) with a panel
of 4 primer pairs specific for polymorphic microsatellite
regions to identify an informative locus. The previously
described primer sequences are designated as b7, h10, h12,
h4 [21]. As a modification of the technique described by
Oberkircher et al. [21], we conjugated the 3′ primer of each
pair to ﬂuorescent 5-6 carboxyﬂuorescein (6-FAM) or Hex
dye (Genosys Biotechnologies, The Woodlands, TX). All
reactions were performed in a total volume of 50 mL, with
0.03 µg genomic DNA; 10 mmol/L Tris-HCl (pH 8.3); 1.5
mmol/L Mg2Cl; 50 mmol/L KCl; 0.01% (wt/vol) gelatin;
200 µmol/L each of dGTP, dATP, dTTP, and dCTP; 0.5 U
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AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk,
CT); and 10% DMSO. Each cycle consisted of denaturation
at 94°C for 5 minutes, primer annealing at 55°C for 60 sec-
onds, and primer extension at 72°C for 60 seconds for
40 cycles. A ﬁnal 10-minute extension at 72°C followed the
last cycle. The ampliﬁcation products were electrophoresed
on an automated 373 or 377 DNA sequencer (Applied
Biosystems, Foster City, CA) using a 4.75% or 4% polyacryl-
amide gel, respectively, and data were analyzed by GeneScan
software (Perkin Elmer Cetus Instruments, Emeryville, CA).
A locus was defined as informative if analysis of recipient
and donor samples before transplant showed a unique band
for the recipient, a unique band for the donor, or a unique
band for each. Once an informative locus was identified,
genomic DNA from subsequent pre- and post-DLI samples
at various time points was amplified with that specific
primer to follow hematopoietic chimerism. To quantify the
donor:recipient ratio in mixed chimeras, results were
referred to standard ampliﬁcations of different mixtures of
donor and recipient pretransplant DNA (ranging from
90:10 to 10:90).
In 1 sex-mismatched donor-recipient pair, we were not
able to identify any informative microsatellite locus, and PCR
amplification of the sY14-SRY (testis determining factor)
gene on the Y chromosome was used to discriminate between
donor (female) and recipient (male) cells. Genomic DNA was
amplified in a total volume of 30 µL using the following
primers: 5′-GAATATTCCCGCTCTCCGGA-3′ and
3′-GCTGGTGCTCCATTCTTGAG-5′. Thirty-ﬁve cycles
of 30 seconds at 94°C, 2 minutes at 58°C, and 2 minutes at
72°C were used, with a ﬁnal extension of 7 minutes at 72°C.
TCR V Repertoire Analysis
PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation and cryopreserved. For TCR Vβ analysis, sam-
ples from different time points were thawed and enriched for
T lymphocytes by immunomagnetic selection of CD3+ cells
using magnetic cell separation (MACS) beads (Milteny
Biotech, Sunnyvale, CA).
Our method for TCR Vβ repertoire analysis has been
described [22-24]. Briefly, RNA was extracted from T-cell
preparations using the RNAStat-60 kit (Tel-Test,
Friendswood, TX), and first-strand cDNA was generated
from 2 µg total RNA using random hexanucleotides (Phar-
macia Biotech, Piscataway, NJ) and reverse transcriptase
(Superscript, Gaithersburg, MD). Each Vβ segment was
ampliﬁed with 1 of the 26 Vβ subfamily–speciﬁc primers and
a Cβ primer recognizing both Cβ1 and Cβ2 regions. The Cβ
primer was conjugated to ﬂuorescent dye 6-FAM (Applied
Biosystems, Foster City, CA) for complementarity-determin-
ing region 3 (CDR3) size analysis. The amplification was
performed over 30 cycles in a ﬁnal volume of 100 µL on a
DNA thermal cycler (Perkin-Elmer, Norwalk, CT).
TCR  Chain CDR3 Fragment Size Analysis
The size distribution of each ﬂuorescent PCR product
was determined by electrophoresis on an automated 373
DNA sequencer (Applied Biosystems) using a 5.5% polya-
crylamide gel and the data analyzed by GeneScan software
(Perkin Elmer, Foster City, CA). Because the position of the
5′ and 3′ primers are ﬁxed, fragment size differences within
each Vβ subfamily are due entirely to different complemen-
tary-determining region 3 (CDR3) region lengths, reﬂecting
junctional diversity and N-random nucleotide insertions in
the V-D-J region. Peaks corresponding to in-frame tran-
scripts are detected at 3-nucleotide intervals. As described
previously, a normal transcript size distribution, reflecting
polyclonal cDNA, contains 8 to 10 peaks for each TCR Vβ
subfamily with a Gaussian size distribution [22-26]. The
appearance of dominant peaks indicates the presence of excess
cDNA of identical size, suggesting the presence of an oligo-
clonal or clonal T-cell population. The absence of any peaks
after PCR ampliﬁcation indicates the absence of any T cells
using a speciﬁc Vβ subfamily of TCR genes.
TCR  Chain CDR3 Complexity Scoring
The overall complexity within a TCR Vβ subfamily was
determined by counting the number of discrete peaks per
subfamily [24]. Subfamilies were graded on a score of 0 to 8
based on the degree of complexity. A score of 0 was assigned
if a subfamily was absent, a score of 1 was given if a subfam-
ily demonstrated only a single monoclonal peak, a score of 2
was given for a biclonal proﬁle, and so on. Finally, a score of
8 denoted a “normal” appearing CDR3 pattern of 8 to
10 peaks with a complex, diverse, and polyclonal appear-
ance. The overall TCR Vβ complexity score per sample was
calculated as the summation of the number of subfamilies
per score category, with a maximum possible score of 208
(8 × 26). Based on the TCR Vβ complexity scores of 10 nor-
mal donors, we established a score of <142 as abnormal,
based on the 95% lower conﬁdence interval.
RESULTS
Clinical Myeloma Response After CD4+ DLIs
In the present study, we examined 4 patients with
relapsed multiple myeloma who were enrolled in a clinical
trial to determine the toxicity and immunologic effects of
infusion of deﬁned doses of CD4+ donor T cells. In this trial,
it was noted that hematologic responses occurred primarily in
patients with CML and multiple myeloma [9]. To examine
the immunologic effects of DLI associated with clinical
response, we selected for further analysis 3 patients with mul-
tiple myeloma who demonstrated either a complete or partial
response following DLI and 1 patient without evident tumor
response. Clinical characteristics of these 4 patients and their
course after BMT are summarized in the Table. Myeloma
response after DLI was evaluated by serial measurement of
immunoglobulin (Ig) levels and monoclonal paraprotein in
serum and by serial histologic examination of bone marrow
aspirates and biopsies. Serum immunoglobulin levels in
patients 1, 2, and 4 after DLI are summarized in Figure 1.
Patient 3 had light chain disease without detectable serum
paraprotein. Myeloma response in patient 3 was evaluated by
histologic examination of serial marrow biopsies and exami-
nation of urine for the presence of monoclonal light chain.
At 1 month after DLI, patient 1 (Figure 1A) was found
to have decreasing levels of serum paraprotein. Total serum
IgG and myeloma paraprotein levels continued to decrease
slowly over the next year, and marrow biopsies demon-
strated a histologic remission 10 months after DLI. However,
paraprotein remained detectable in serum, and a complete
E. Orsini et al.
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response was not demonstrated until 2 years after DLI.
Beginning 5 months after DLI, this patient developed
lichenoid GVHD of the skin and chronic GVHD of the
liver, requiring treatment with prednisone and cyclosporine.
This patient continues to have evidence of chronic skin
GVHD and also continues in complete remission without
evidence of increased plasma cells in marrow and without
detectable serum paraprotein 4 years after DLI.
Patient 2 (Figure 1B) continued to have increasing levels
of serum monoclonal IgA paraprotein 1 month after DLI, but
decreasing levels were noted 2 months after DLI. The patient
quickly reached normal serum levels of IgA, but monoclonal
protein was always detectable and he never attained a com-
plete remission. Marrow biopsies during this period demon-
strated 5% to 10% plasma cells that expressed a monoclonal
light chain. Four months after DLI, he developed extensive
GVHD of the skin and liver, requiring treatment with pred-
nisone and cyclosporine. The patient remained in a minimal
disease state for 1.5 years after DLI, when progressive disease
was again documented. The initial site of disease progression
was a pleural plasmacytoma.
Patient 3 did not have detectable monoclonal parapro-
tein in serum, but disease regression became evident with
decreased urinary excretion of light chain 2 months after
DLI. A complete response was noted 6 months after DLI,
with absence of urinary light chain excretion and histologi-
cally normal marrow biopsy. The patient relapsed with a
single lytic bone lesion and sinus cavity plasmacytoma
8 months after DLI. This was treated with local radiation
therapy. Patient 3 developed extensive chronic GVHD
10 months after DLI that continued despite treatment with
prednisone and cyclosporine.
Patient 4 (Figure 1C) developed a bone plasmacytoma
1 month after DLI. This was treated with dexamethasone
and local radiation therapy. Serum paraprotein levels con-
tinued to increase for 2 months after DLI but decreased
after this additional systemic and local treatment. He con-
tinued to have stable disease until increasing serum parapro-
tein levels developed 6 months after DLI. No response was
noted after a second DLI. This patient did not develop
GVHD after either the ﬁrst or second DLI.
Expansion of Peripheral Blood T Cells After DLI
Changes in peripheral blood lymphocytes were moni-
tored by serial assessment of the phenotype of circulating
T cells after DLI. Patient 1 was found to have increased
numbers of circulating lymphocytes 1 month after DLI, and
patients 2 and 3 developed lymphocytosis 2 months after
DLI. In these 3 cases, peripheral lymphocytosis coincided
with the initiation of a tumor response, with no lymphocy-
tosis noted in patient 4. The results of the phenotypic analy-
sis of PBMCs in the first 3 months after DLI for all
4 patients is summarized in Figure 2. When compared with
baseline levels before DLI, patient 1 was found to have a
2-fold increase in CD3+ cells 1 month after DLI. These cells
were predominantly CD8+. Patients 2 and 3 were noted to
have 2- and 4.5-fold increases, respectively, in CD3+ cells
2 months after DLI. In both of these patients, this change
was due to increases in both CD4+ and CD8+ cells. Similar
changes in circulating T cells were not noted in patient 4.
Changes in Hematopoietic Chimerism After DLI
The relative contributions of recipient and donor
hematopoiesis were examined by serial analysis of polymor-
phic microsatellite loci by PCR amplification of genomic
DNA obtained from patient PBMCs. In patient 2, no infor-
mative patient-donor microsatellite pair was identiﬁed, and
we therefore used a Y chromosome-speciﬁc nonquantitative
PCR assay to distinguish between patient (male) and donor
(female) cells. As shown in Figure 3A, patient and donor
DNA could be easily distinguished by the presence of
unique proﬁles using this method in patient 1. Before DLI,
no evidence of donor DNA could be detected indicating
that PBMCs were entirely derived from recipient hemato-
poiesis. In contrast, PBMCs obtained 1 month after DLI
contained only donor DNA, indicating rapid conversion to
complete donor hematopoiesis in this patient. Results of
PCR amplification of a Y chromosome-specific marker in
patient 2 also indicated the presence of recipient cells
before and at 1 month after DLI (Figure 3B). Although this
sensitive assay does not provide an assessment of the rela-
tive contribution of recipient cells at these 2 time points, all
subsequent PCR assays beginning at 2 months after DLI no
Patient Characteristics*
Treatment BMT to Relapse CD4 Cells
Donor Myeloma Before Status Relapse, to DLI, Infused,
Patient Age, y Sex Sex Paraprotein BMT at BMT mo mo 108/kg
1 40 M F IgG MP Minimal disease 6 3 1
Dex
HD-Cy
2 42 M F IgA VAD Minimal disease 53 9 1.5
3 46 F F Light chain  VAD Partial response 38 5 1
MP
HD-Cy
4 56 M M IgG MP Minimal disease 9 7 1.5
CBVM
VAD
HD-Cy
*BMT indicates bone marrow transplant; DLI, donor lymphocyte infusion; Ig, immunoglobin; MP, melphalan, prednisone; Dex, dexamethasone;
HD-Cy, high-dose cyclophosphamide; VAD, vincristine, doxorubicin, dexamethasone; CBVM, cyclophosphamide, carmustine, vincristine, melphalan.
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Figure 1. Measurement of disease status after donor lymphocyte infusion (DLI). A. Serum levels of immunoglobulin G (IgG) for patient 1. B. Serum
levels of IgA for patient 2. C. Serum levels of IgG for patient 4. Serum levels are reported at the time of DLI and in the following months.  indicates a
complete remission (no detection of monoclonal protein); , the presence of monoclonal paraprotein. The onset of graft-versus-host disease (GVHD),
clinical response, and additional therapies are also indicated.
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Figure 2. Changes in circulating T cells after donor lymphocyte infusion (DLI). Absolute numbers of CD3+, CD8+, and CD4+ cells were calculated
after determining the absolute number of mononuclear cells and percent positive cells by immunostaining. The relative increase or decrease of each
population in comparison to baseline values obtained before DLI is represented for every patient (Pt.).
Figure 3. Hematopoietic chimerism after donor lymphocyte infusion (DLI). A. Detection of donor and patient-derived microsatellite polymor-
phisms in serial blood samples from patient 1. Results from patient and donor blood samples before bone marrow transplantation, before DLI, and 1
month after DLI. B. Detection of Y chromosome–speciﬁc DNA (sY14-SRY) indicating the presence of recipient cells in serial peripheral blood
samples from patient 2. bp indicates base pair.
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longer detected the presence of residual recipient cells in
PBMCs. This indicated a conversion to complete donor
hematopoiesis at 2 months after DLI and the subsequent
maintenance of this status.
The results of all chimerism assays for the 4 patients are
summarized in Figure 4. All 4 myeloma patients had evi-
dence of substantial mixed chimerism in PBMCs before
DLI. In patients 1 and 4, donor cells could not be detected
using this sensitive method. Patients 1, 2, and 3 rapidly con-
verted to complete donor hematopoiesis within 2 months
after DLI. In contrast, patient 4 showed persistence of com-
plete recipient hematopoiesis throughout the 15-month
period of observation.
TCR Repertoire Complexity After DLI
The complexity of the T-cell repertoire after DLI was
examined by analysis of PCR-amplified products of each of
the 24 TCR Vβ subfamilies. Two Vβ subfamilies (Vβ5 and
Vβ13) require 2 sets of variable region primers to visualize
the entire subfamily gene, thus producing 26 different pro-
files for each sample analyzed. This method specifically
amplifies the CDR3 region used by each mature T cell.
Normal polyclonal populations, therefore, exhibit a diverse
pattern of 8 to 10 peaks in a Gaussian distribution for each
Vβ subfamily [25,26]. The results of this analysis for
peripheral blood samples obtained before DLI and
1 month after DLI in patient 1 are shown in Figure 5.
Although some Vβ families exhibited normal profiles (Vβ4,
Vβ5, Vβ9), the majority of profiles in the pre-DLI sample
were abnormal, exhibiting clonal (Vβ14), oligoclonal
(Vβ16), or absent (Vβ23) profiles indicative of a markedly
restricted T-cell repertoire. In contrast, the 1-month post-
DLI sample demonstrated a normal TCR repertoire in
almost all profiles. Although some clonal (Vβ 24) and
oligoclonal (Vβ 16) profiles persisted, the sample overall
indicated a relatively rapid improvement in the complexity
of the TCR repertoire in this interval.
To compare changes in TCR repertoire complexity in
different patients and in different samples after DLI, we
used a scoring system to quantify the degree of complexity
of each CDR3 proﬁle [24]. In previous studies, analysis of
samples from 10 normal donors was used to deﬁne a score
of 142 as the lower limit of normal. Results of this analysis
for peripheral blood lymphocyte (PBL) obtained from each
of the 4 myeloma patients for 1 year after DLI are shown in
Figure 6. Patients 2 and 4 had relatively normal complexity
scores before DLI and did not demonstrate any substantial
changes in repertoire complexity after DLI. In contrast,
patients 1 and 3 had significantly low complexity scores
before DLI. Repertoire complexity normalized at 1 month
after DLI in patient 1 and at 2 months after DLI in patient
3. This normalization of TCR repertoire was maintained
for at least 1 year in both patients.
Correlation of Hematopoietic Chimerism With
Myeloma Response and GVHD
The results of our analysis of hematopoietic chimerism
are summarized in Figure 7 and shown in relation to the
demonstration of myeloma response and the development
of GVHD in each patient. Patient 4 continued to demon-
strate predominantly, recipient hematopoiesis throughout
this period. No changes in repertoire complexity were
observed, and neither a myeloma response nor GVHD
developed after DLI. In contrast, patients 1, 2, and 3
demonstrated conversion to complete donor hematopoiesis
1 to 2 months after DLI. This conversion coincided with
the initiation of clinical myeloma response. In patients 1 and
3, the conversion to donor hematopoiesis also coincided
with the normalization of TCR repertoire complexity.
Changes in hematopoietic chimerism and TCR repertoire
did not appear to coincide with the onset of either acute or
chronic GVHD after DLI. With subsequent relapse of
myeloma cells in patients 2 and 3, there was no change in
hematopoietic chimerism, and these patients continued to
demonstrate persistence of complete donor hematopoiesis.
DISCUSSION
The clinical responses to DLI in patients with relapsed
multiple myeloma provide direct evidence for the suscepti-
Figure 4. Summary of changes in hematopoietic chimerism after donor lymphocyte infusion (DLI). The relative contribution of patient and donor
hematopoiesis in serial blood samples pre- and post-DLI is represented for every patient. In patient 2, the nonquantitative nature of the polymerase
chain reaction method used does not allow the precise quantitation of the patient-derived component detected pre-DLI.
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bility of multiple myeloma cells to immunotherapeutic
approaches using adoptive transfer of allogeneic T cells
[5,8,9]. Nevertheless, the immunologic mechanisms that
mediate this GVM effect, as well as the target antigens for
this response, have not been established. The present stud-
ies were undertaken to characterize the immunologic effects
of donor T-cell infusions in patients with multiple myeloma.
These studies demonstrated that an effective immune
response directed against myeloma tumor cells began
approximately 4 to 8 weeks after DLI and coincided with
the elimination of normal recipient hematopoietic cells and
conversion to complete donor hematopoiesis. The associa-
tion of clinical response with the establishment of complete
donor hematopoiesis has previously been observed in
patients with CML responding to DLI [10,11,13]. Although
it is possible that the immune responses against tumor cells
and normal hematopoietic progenitors are distinct, the pres-
ent results suggest that the antitumor response in patients
with multiple myeloma is directed against target antigens
expressed on normal hematopoietic progenitor cells as well
as malignant cells in the recipient. Interestingly, examina-
tion of hematopoietic chimerism in the single patient who
did not respond to DLI demonstrated no change in
chimerism and persistence of predominant recipient
hematopoiesis. Although we were able to examine only a
single nonresponding patient, this ﬁnding suggests that the
lack of antimyeloma response in this individual may be due
to the inability to generate an immune response directed
against common antigens expressed on recipient hemato-
poietic cells rather than resistance of the myeloma cells to
immune-mediated destruction. Alternatively, it is also possi-
ble that the lack of immunologic effect may have been due
to rejection of donor cells. No phenotypic changes associ-
ated with rejection were observed after DLI [27], but studies
Figure 5. T-cell receptor (TCR) complementarity-determining region 3 (CDR3) diversity in peripheral blood T cells. A. CDR3 size distribution
profiles for each of 24 TCR Vb gene subfamilies for samples obtained before donor lymphocyte infusion (DLI). B. Comparison with results
obtained 1 month post-DLI in patient 1.
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to examine this alternative explanation for resistance to DLI
should be carried out to address this issue.
Further analysis in these selected individuals also demon-
strated that the 3 responding patients developed varying
degrees of T-cell lymphocytosis at the time that the
antimyeloma response became clinically apparent. Although
the DLI consisted of deﬁned numbers of CD4+ T cells that
had been depleted of CD8+ cells ex vivo, the lymphocytosis
consisted primarily of CD8+ cells in 1 patient and of both
CD4+ and CD8+ T cells in the other 2 responders. Interest-
ingly, this lymphocytosis was noted 4 to 8 weeks after DLI
and also occurred as the patients were converting from
mixed chimerism to complete donor hematopoiesis. These
cells in peripheral blood were therefore of donor origin, but
it is not known whether they were directly derived from the
lymphocyte infusion or whether they may have been derived
from cells that had previously engrafted during the primary
allogeneic marrow transplant. The finding that many of
these cells were CD8+ suggests that they were not contained
in the DLI, which had been depleted of CD8+ cells before
infusion. However, because these cells are all derived from
the same normal donor, these 2 alternative possibilities can
only be distinguished in experiments in which genetic mark-
ers are introduced into the DLI product before infusion
[28,29]. Such experiments would be very helpful in deter-
mining whether the CD4+ DLI produced a direct antitumor
effect or whether these cells primarily acted by providing
T-cell help, with subsequent expansion of an effector popula-
tion that had previously been suppressed or otherwise unable
to mediate an effective antimyeloma response in vivo.
Another striking ﬁnding that coincided with the initia-
tion of the antimyeloma response after DLI, was normaliza-
tion of the TCR repertoire in 2 of the 3 responding
patients. In previous studies in patients with CML and mul-
tiple myeloma, we found that serial analysis of TCR Vβ
repertoire revealed the expansion of clonal T-cell popula-
tions in peripheral blood after DLI [22,23]. These clonal
T-cell populations became evident at the initiation of the
antitumor response and persisted for prolonged periods.
Distinct clonal T-cell populations could be detected in
peripheral blood when clinical GVHD developed. Normal-
ization of TCR repertoire was also noted in CML patients
after DLI, but improvement in TCR repertoire occurred
very slowly in responding individuals: approximately 1 year
was required before a normal TCR repertoire was achieved
[22]. A similar time period is required for normalization of
TCR repertoire after primary allogeneic stem cell trans-
plantation [24]. The rapidity of the improvement in TCR
repertoire in the patients with multiple myeloma may indi-
cate that the polyclonal T cells appearing in the peripheral
blood after DLI, in these patients, do not represent the dif-
ferentiation of new T cells from hematopoietic progenitor
cells. Abnormal TCR proﬁles, such as those seen in patients
1 and 3, may be due to the presence of oligoclonal T-cell
expansions that obscure the presence of polyclonal T cells in
the assay. In these 2 patients, normalization of TCR reper-
toire coincided with the conversion to complete donor
hematopoiesis. A recent analysis of TCR repertoire after
allogeneic BMT demonstrated that abnormal TCR reper-
toire profile may be due to the relative overexpansion of
Figure 6. Summary of T-cell receptor (TCR) repertoire complexity scores after donor lymphocyte infusion (DLI). The overall TCR complexity
score for all 24 Vb gene subfamilies was calculated for peripheral blood samples obtained in every patient before DLI and at various times after DLI.
The dotted line represents the lower limit of the normal range of TCR Vb complexity scores for 10 normal individuals.
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oligoclonal T cells, rather than the loss of a polyclonal
repertoire [30]. Thus, the elimination of recipient-derived
oligoclonal T cells in our patients after DLI appeared to
allow the rapid expansion of polyclonal donor-derived
T cells and reestablishment of a normal T-cell repertoire.
This is a more likely explanation for the normalization of
TCR repertoire in our patients than the generation of new
T cells from undifferentiated lymphocyte progenitor cells.
T cells are presumed to be the principal mediators of
GVL activity as well as GVHD, but it is not known whether
GVL and GVHD are identical or distinct immunologic
effects. To address this issue, 2 clinical trials examined
whether depletion of CD8+ T cells from the DLI can selec-
tively reduce the incidence of GVHD without affecting
GVL activity [9,31]. Interestingly, both of these studies sug-
gested that selective infusion of CD4+ donor T cells reduces
the risk of acute and chronic GVHD without eliminating
GVL activity. Nevertheless, 3 of the 4 patients described in
this report developed GVHD after CD8-depleted DLI.
Each of these patients, however, received relatively large
numbers of donor cells, and GVHD occurred several weeks
or months after the initial response against myeloma cells
began. Thus, both the antimyeloma response and the con-
version to complete donor hematopoiesis occurred before
any clinical evidence of GVHD was observed. Moreover,
the persistence of active GVHD did not prevent myeloma
relapse in 2 patients. Taken together, these observations
provide support for the notions that GVHD is a distinct
Figure 7. Correlation of changes in hematopoietic chimerism with myeloma response and graft-versus-host disease (GVHD) after donor lympho-
cyte infusion. CR indicates complete response; PR, partial response; pt, patient.
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immunologic process and that it may be possible to develop
methods for selectively enhancing GVL without concomi-
tant increase in the toxicity associated with GVHD. Further
characterization of both of these immunologic responses is
necessary to determine the immunologic basis for these
clinical observations.
Although the antimyeloma response became evident rela-
tively soon after DLI, not all responding patients achieved a
complete response, and prolonged periods of 1 to 2 years
were required before this could be achieved. The prolonged
period required to eradicate relatively small numbers of resid-
ual myeloma cells is similar to the time required to achieve
molecular remission in patients with CML. However, this
appears to be very different from the response directed
against recipient hematopoietic cells, which resulted in the
very rapid and complete elimination of relatively large num-
bers of normal cells. Although the method for quantitation of
hematopoietic chimerism in patients 1, 3, and 4 was not
developed to detect small numbers of recipient cells, the PCR
assay used in patient 2 targeted a Y chromosome–
specific antigen and therefore provides a very sensitive
method for detecting residual recipient cells. This assay does
not allow us to provide an accurate estimate of the percentage
of recipient cells in the samples tested, but once conversion to
donor hematopoiesis occurred, no residual recipient male
cells could be detected in repeated tests. Thus, in contrast to
the relatively slow elimination of myeloma cells, these obser-
vations indicate that complete elimination of residual recipi-
ent hematopoiesis occurred very rapidly after DLI.
Unfortunately, 2 of the patients who converted to com-
plete donor hematopoiesis subsequently relapsed. Relapse
occurred initially in extramedullary sites, but despite reemer-
gence of myeloma tumor cells, blood samples in both indi-
viduals remained entirely of donor origin. Although the rea-
sons for relapse in these individuals have not been identiﬁed,
this observation suggests that relapse of myeloma may be due
to the development of resistance to immune destruction
rather than to suppression of the donor immune response.
Similar observations in patients with relapsed melanoma
after immunotherapy have previously identified several
mechanisms whereby tumor cells can become resistant to
immune-mediated attack [32,33]. Further studies will be nec-
essary to identify the target antigens of this response as well
as the mechanisms of tumor escape. With further characteri-
zation of the antimyeloma response in additional patients, it
may be possible to improve the durability of the antitumor
response and extend this immunotherapeutic approach to
other patient populations that do not currently respond to
this treatment.
REFERENCES
1. Kolb HJ, Mittermuller J, Clem C, et al. Donor leukocyte transfu-
sions for treatment of recurrent chronic myelogenous leukemia in
marrow transplant patients. Blood. 1990;76:2462-2465.
2. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infu-
sions in 140 patients with relapsed malignancy after allogeneic
bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-
leukemia effect of donor lymphocyte transfusions in marrow
grafted patients. European Group for Blood and Marrow Trans-
plantation Working Party Chronic Leukemia. Blood. 1995;
86:2041-2050.
4. Porter D, Collins R, Shpilberg O, et al. Long-term follow-up of
patients who achieved complete remission after donor leukocyte
infusions. Biol Blood Marrow Transplant. 1999;5:253-261.
5. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma
effect: proof of principle. Blood. 1996;87:1196-1198.
6. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J.
Adoptive immunotherapy for relapsed multiple myeloma after
allogeneic bone marrow transplantation (BMT): evidence for a
graft-versus-myeloma effect. Leukemia. 1997;11:281-283.
7. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK,
Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet.
1996;347:800-801.
8. Lokhorst H, Schattenberg A, Cornelissen J, Thomas L, Verdonck
L. Donor leukocyte infusions are effective in relapsed multiple
myeloma after allogeneic bone marrow transplantation. Blood.
1997;90:4206-4211.
9. Alyea E, Soiffer R, Canning C, et al. Toxicity and efficacy of
defined doses of CD4+ donor lymphocytes for treatment of
relapse after allogeneic bone marrow transplant. Blood. 1998;
91:3671-3680.
10. Keil F, Haas O, Fritsch G, et al. Donor leukocyte infusion for
leukemic relapse after allogeneic marrow transplantation: lack of
residual donor hematopoiesis predicts aplasia. Blood. 1997;89:
3113-3117.
11. Rapanotti MC, Arcese W, Buffolino S, et al. Sequential molecu-
lar monitoring of chimerism in chronic myeloid leukemia
patients receiving donor lymphocyte transfusion for relapse after
bone marrow transplantation. Bone Marrow Transplant. 1997;
19:703-707.
12. Verdonck L, van Blokland W, Bosboom-Kalsbeek E, et al. Com-
plete donor T cell chimerism is accomplished in patients trans-
planted with bone marrow grafts containing a ﬁxed low number
of T cells. Bone Marrow Transplant. 1996;18:389-395.
13. Baurmann H, Nagel S, Binder T, et al. Kinetics of the graft-
versus-leukemia response after donor leukocyte infusions for
relapsed chronic myeloid leukemia after allogeneic bone marrow
transplantation. Blood. 1998;92:3582-3590.
14. Gardiner N, Lawler M, O’Riordan J, et al. Monitoring of lineage-
speciﬁc chimerism allows early prediction of response following
donor lymphocyte infusions for relapsed chronic myeloid
leukaemia. Bone Marrow Transplant. 1998;21:711-719.
15. Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of
clonogenic leukemic cells, remission bone marrow and HLA-
identical donor bone marrow by CD8+ or CD4+ minor histocom-
patibility antigen-speciﬁc cytotoxic T lymphocytes. J Clin Invest.
1995;96:877-883.
16. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lympho-
cyte-defined human minor histocompatibility antigens with a
restricted tissue distribution. Blood. 1998;91:2197-2207.
17. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class
I-minor histocompatibility antigen peptide complexes demon-
strate minor histocompatibility antigen-speciﬁc cytotoxic T lym-
phocytes in patients with graft-versus-host disease. Nat Med.
1999;5:839-842.
18. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunother-
apy of relapsed leukemia with ex vivo-generated cytotoxic T lym-
phocytes specific for hematopoietic system-restricted minor
histocompatibility antigens. Blood. 1999;93:2336-2341.
19. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-
E. Orsini et al.
386
host disease by selective depletion of CD6-positive T lympho-
cytes from donor bone marrow. J Clin Oncol. 1992;10:1191-1200.
20. Soiffer R, Fairclough D, Robertson M, et al. CD6 depleted allo-
geneic bone marrow transplantation for acute leukemia in first
complete remission. Blood. 1997;89:3039-3047.
21. Oberkircher AR, Strout MP, Herzig GP, Fritz PD, Caligiuri MA.
Description of an efﬁcient and highly informative method for the
evaluation of hematopoietic chimerism following allogeneic bone
marrow transplantation. Bone Marrow Transplant. 1995;16:695-
702.
22. Claret E, Alyea E, Orsini E, et al. Characterization of T cell
repertoire in patients with graft-versus-leukemia following donor
lymphocyte infusion. J Clin Invest. 1997;100:855-866.
23. Orsini E, Alyea E, Schlossman R, et al. Changes in T cell recep-
tor repertoire associated with graft-versus-tumor effect and graft-
versus-host disease in patients with relapsed multiple myeloma
receiving donor lymphocyte infusion. Bone Marrow Transplant.
2000;25:623-632.
24. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell
receptor repertoire diversity following T-cell depleted allogeneic
bone marrow transplantation is related to hematopoietic
chimerism. Blood. 2000;95:352-359.
25. Pannetier C, Cochet M, Darche S, et al. The sizes of the CDR3
hypervariable regions of the murine T-cell receptor beta chains
vary as a function of the recombined germ-line segments. Proc
Natl Acad Sci U S A. 1993;90:4319-4323.
26. Gorski J, Yassai M, Zhu X, et al. Circulating T cell repertoire
complexity in normal individuals and bone marrow recipients ana-
lyzed by CDR3 size spectratyping: correlation with immune sta-
tus. J Immunol. 1994;152:5109-5119.
27. Bosserman LD, Murray C, Takvorian T, et al. Mechanism of
graft failure in HLA-matched and HLA-mismatched bone
marrow transplant recipients.  Bone Marrow Transplant.
1989;4:239-245.
28. Economou J, Belldegrun A, Glaspy J, et al. In vivo trafﬁcking of
adoptively transferred interleukin-2 expanded tumor-infiltrating
lymphocytes and peripheral blood lymphocytes. J Clin Invest.
1996;97:515-521.
29. Jacob J, Baltimore D. Modelling T-cell memory by genetic mark-
ing of memory T cells in vivo. Nature. 1999;399:593-597.
30. Battaglia M, Andreani M, Manna M, et al. Coexistence of two
functioning T-cell repertoires in healthy ex-thalassemics bearing
a persistent mixed chimerism years after bone marrow transplan-
tation. Blood. 1999;94:3432-3438.
31. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte
infusion as treatment for relapsed chronic myelogenous leukemia
after allogeneic bone marrow transplantation. Blood. 1995;
86:4337-4343.
32. Hicklin D, Wang Z, Arienti F, et al. Beta2-microglobulin muta-
tions, HLA class I antigen loss, and tumor progression in
melanoma. J Clin Invest. 1998;101:2720-2729.
33. Lee P, Yee C, Savage P, et al. Characterization of circulating
T cells specific for tumor-associated antigens in melanoma
patients. Nat Med. 1999;5:677-685.
